The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM
B. M. Feldman(University of Toronto), V. Blanchette(Hospital for Sick Children), Björn Lundin(Lund University), Monika Bullinger(Zimmer Biomet (Germany)), Alok Srivastava(M.J.P. Rohilkhand University), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Andrea Doria(University of Padua), F. M. DELANEY, Alec Miners(London School of Hygiene & Tropical Medicine), Marilyn J. Manco‐Johnson(University of Colorado Anschutz Medical Campus), Paul Giangrande, Sharon Funk(University of Colorado Health), W. Schramm(Ludwig-Maximilians-Universität München), P C Scriba(Ludwig-Maximilians-Universität München)
Cited by 22
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
|Journal of Clinical Epidemiology|1998|2.9k
Translating Health Status Questionnaires and Evaluating Their Quality
|Journal of Clinical Epidemiology|1998|921
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913